{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:54:41Z","timestamp":1783457681801,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21924-4","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:11:11Z","timestamp":1761912671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types"],"prefix":"10.1038","volume":"15","author":[{"given":"Tiyun","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyi","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"21924_CR1","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376. https:\/\/doi.org\/10.1056\/NEJMoa2201445 (2022).","journal-title":"N. Engl. J. Med."},{"key":"21924_CR2","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976\u20131986. https:\/\/doi.org\/10.1056\/NEJMoa1716078 (2018).","journal-title":"N. Engl. J. Med."},{"key":"21924_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690 (2012).","journal-title":"N. Engl. J. Med."},{"key":"21924_CR4","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde, A. et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: A randomized phase 2 trial. Nat. Med. 29, 2278\u20132285. https:\/\/doi.org\/10.1038\/s41591-023-02498-y (2023).","journal-title":"Nat. Med."},{"key":"21924_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","volume":"23","author":"A van Weverwijk","year":"2023","unstructured":"van Weverwijk, A. & de Visser, K. E. Mechanisms driving the immunoregulatory function of cancer cells. Nat. Rev. Cancer 23, 193\u2013215. https:\/\/doi.org\/10.1038\/s41568-022-00544-4 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"21924_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","volume":"23","author":"AT Ruffin","year":"2023","unstructured":"Ruffin, A. T. et al. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat. Rev. Cancer 23, 173\u2013188. https:\/\/doi.org\/10.1038\/s41568-022-00531-9 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"21924_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","volume":"21","author":"K DePeaux","year":"2021","unstructured":"DePeaux, K. & Delgoffe, G. M. Metabolic barriers to cancer immunotherapy. Nat. Rev. Immunol. 21, 785\u2013797. https:\/\/doi.org\/10.1038\/s41577-021-00541-y (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"21924_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang, Y. et al. Improving immune-vascular crosstalk for cancer immunotherapy. Nat. Rev. Immunol. 18, 195\u2013203. https:\/\/doi.org\/10.1038\/nri.2017.145 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"21924_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/CJI.0000000000000133","volume":"39","author":"N Mousavi Niri","year":"2016","unstructured":"Mousavi Niri, N. et al. Improved anti-treg vaccination targeting foxp3 efficiently decreases regulatory T cells in mice. J. Immunother. 39, 269\u2013275. https:\/\/doi.org\/10.1097\/CJI.0000000000000133 (2016).","journal-title":"J. Immunother."},{"key":"21924_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1158\/0008-5472.CAN-06-2903","volume":"67","author":"S Nair","year":"2007","unstructured":"Nair, S., Boczkowski, D., Fassnacht, M., Pisetsky, D. & Gilboa, E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Can. Res. 67, 371\u2013380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2903 (2007).","journal-title":"Can. Res."},{"key":"21924_CR11","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","volume":"25","author":"R Hassan","year":"2019","unstructured":"Hassan, R. et al. Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 25, 5787\u20135798. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0070 (2019).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"21924_CR12","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/onc.2011.395","volume":"31","author":"Y Chen","year":"2012","unstructured":"Chen, Y. et al. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene 31, 2140\u20132152. https:\/\/doi.org\/10.1038\/onc.2011.395 (2012).","journal-title":"Oncogene"},{"key":"21924_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.15698\/cst2019.05.185","volume":"3","author":"MH Andersen","year":"2019","unstructured":"Andersen, M. H. The targeting of tumor-associated macrophages by vaccination. Cell Stress 3, 139\u2013140. https:\/\/doi.org\/10.15698\/cst2019.05.185 (2019).","journal-title":"Cell Stress"},{"key":"21924_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.omto.2019.06.002","volume":"14","author":"Z Lin","year":"2019","unstructured":"Lin, Z. et al. A PD-L1-based cancer vaccine elicits antitumor immunity in a mouse melanoma model. Mol. Ther. Oncol. 14, 222\u2013232. https:\/\/doi.org\/10.1016\/j.omto.2019.06.002 (2019).","journal-title":"Mol. Ther. Oncol."},{"key":"21924_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006755","author":"CL Lorentzen","year":"2023","unstructured":"Lorentzen, C. L., Kjeldsen, J. W., Ehrnrooth, E., Andersen, M. H. & Marie Svane, I. Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO\/PD-L1 targeting peptide vaccine and nivolumab. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2023-006755 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"21924_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000605","author":"S Dey","year":"2020","unstructured":"Dey, S. et al. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-000605 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"21924_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-21-0457","volume":"10","author":"R Nandre","year":"2022","unstructured":"Nandre, R. et al. IDO vaccine ablates immune-suppressive myeloid populations and enhances antitumor effects independent of tumor cell IDO status. Cancer Immunol. Res. 10, 571\u2013580. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0457 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"21924_CR18","doi-asserted-by":"publisher","first-page":"2026020","DOI":"10.1080\/2162402X.2022.2026020","volume":"11","author":"SK Bendtsen","year":"2022","unstructured":"Bendtsen, S. K. et al. Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment. Oncoimmunology 11, 2026020. https:\/\/doi.org\/10.1080\/2162402X.2022.2026020 (2022).","journal-title":"Oncoimmunology"},{"key":"21924_CR19","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/2326-6066.CIR-21-0280","volume":"9","author":"M Aaboe Jorgensen","year":"2021","unstructured":"Aaboe Jorgensen, M. et al. Arginase 1-based immune modulatory vaccines induce anticancer immunity and synergize with anti-PD-1 checkpoint blockade. Cancer Immunol. Res. 9, 1316\u20131326. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0280 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"21924_CR20","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","volume":"27","author":"JW Kjeldsen","year":"2021","unstructured":"Kjeldsen, J. W. et al. A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma. Nat. Med. 27, 2212\u20132223. https:\/\/doi.org\/10.1038\/s41591-021-01544-x (2021).","journal-title":"Nat. Med."},{"key":"21924_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong, Y., Lin, Y., Wei, T. & Cheng, Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv. Mater. 35, e2303261. https:\/\/doi.org\/10.1002\/adma.202303261 (2023).","journal-title":"Adv. Mater."},{"key":"21924_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150. https:\/\/doi.org\/10.1038\/s41586-023-06063-y (2023).","journal-title":"Nature"},{"key":"21924_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112. https:\/\/doi.org\/10.1038\/s41586-020-2537-9 (2020).","journal-title":"Nature"},{"key":"21924_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401. https:\/\/doi.org\/10.1038\/nature18300 (2016).","journal-title":"Nature"},{"key":"21924_CR25","unstructured":"Percie du Sert, N. H. V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., Pearl, E. J., Petersen, O., Rawle, F., Peynolds, P., Rooney, K., Sena, E. S., Silberberg, S. D., Steckler, T. & Wurbel, H. The ARRIVE Guidelines 2.0: updated guidelines for reporting animal research."},{"key":"21924_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","volume":"13","author":"SM Nguyen","year":"2015","unstructured":"Nguyen, S. M., Thamm, D. H., Vail, D. M. & London, C. A. Response evaluation criteria for solid tumours in dogs (v1.0): A veterinary cooperative oncology group (VCOG) consensus document. Vet. Comp. Oncol. 13, 176\u2013183. https:\/\/doi.org\/10.1111\/vco.12032 (2015).","journal-title":"Vet. Comp. Oncol."},{"key":"21924_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818\u2013834813. https:\/\/doi.org\/10.1016\/j.cell.2020.09.015 (2020).","journal-title":"Cell"},{"key":"21924_CR28","doi-asserted-by":"publisher","first-page":"2115655","DOI":"10.1080\/2162402X.2022.2115655","volume":"11","author":"I Lecoq","year":"2022","unstructured":"Lecoq, I. et al. CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment. Oncoimmunology 11, 2115655. https:\/\/doi.org\/10.1080\/2162402X.2022.2115655 (2022).","journal-title":"Oncoimmunology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21924-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21924-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21924-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:11:13Z","timestamp":1761912673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21924-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21924"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21924-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38138"}}